Combination treatment for advanced tumors with PTEN loss
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two drugs (CVL237 tablets and serplulimab injection) for people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor (like stomach, lung, breast, ovarian, endometrial, or cervical cancer) that has spread or cannot be removed by surgery.
- Your tumor has been tested and shows loss or low levels of a protein called PTEN.
- You have tried standard treatments and they didn't work, or you couldn't tolerate them, or no standard treatment exists.
- You are able to do daily activities (ECOG performance status 0 or 1).
- You have at least one measurable tumor spot on imaging scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This trial tests an experimental pill (CVL237) for people with advanced solid tumors that lack a protein called PTEN. The study aims to see if the pill can help control the cancer and shrink tumors.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.